L8 ANSWER 75 OF 76 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 137:37642 CA <<LOGINID::20090720>>

TITLE: Preparation and formulation of a quinolinone compound for treatment of airway disorders

INVENTOR(S):

Cuenoud, Bernard; Fairhurst, Robin Alec; Lowther,

Nicholas

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft mbH; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.				KIND		DATE		APPLICATION NO.					DATE				
WO	WO 2002045703				A3 20030313				WO 2001-EP14122				20011200				
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LT,	LU,
							MX,										SG,
							TT,										
	RW:				CY,	DE,	DK,	ES,	FΙ,	FR,	GB,	GR,	ΙE,	ΙT,	LU,	MC,	NL,
		PT,	SE,	TR													
CA	A 2427282				A1 20020613				CA 2001-2427282						20011203		
AU	2002017082			A	A 20020618				CA 2001-2427282 AU 2002-17082 EP 2001-999366					20011203			
EP	1341542			AZ 20030910				EP 2001-999366					20011203				
EP	1341:	342	DE	CII	BI	DIZ	ES,	U5UZ	CD	CD.	T.T.		T TT	NIT	C.E.	140	DT
	ĸ:						RO,					ы,	LU,	NL,	SE,	M.	Р1,
HII	20031	16,	71	ы,	12	EI,	2003	1128	CI,	нп 2	117	2571			2	0011	20.3
HII	2003002571			A3 20051120				HU 2003-2571					20011203				
BR	2001015910			A 20040120				BR 2001-15910				20011203					
JP	2004514739			T 20040520				BR 2001-15910 JP 2002-547487 NZ 2001-525731 AU 2002-217082 CN 2001-820032 RU 2003-119549 EP 2007-100048				20011203					
NZ	525731			Ā	A 20041126				NZ 2001-525731					20011203			
AU	2002217082			B2	B2 20050407				AU 2002-217082					20011203			
CN	1212119			C	C 20050727			CN 2001-820032					20011203				
RU	2292890			C2	2 20070210			RU 2003-119549					20011203				
EP	1772142			A2	.2 20070411			EP 2007-100048 FI, FR, GB, GR, IE, I					20011203				
	R:	AT,	BE,	CH,	CY,	DL,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LI,	LU,	MC,
		NL,	PT,	SE,	TR,	RO,	SI										
AT	3610	77			T		2007	0515		AT 2	2001-	9993	66		2	0011	203
ES	2284	732			T3		2007	1116		ES 2	2001-	9993	66		2	0011	203
11	155/09			A	20081126			AT 2001-999366 ES 2001-999366 IL 2001-155709 ZA 2003-3399					20011203				
ZA.	2003003399			A.	20040423			4A 2003-3399					20030502				
NO	20030000856			7	20030422			IN 2003-CN856 NO 2003-2510					20030602				
NO	2003CN00856 2003002510 325692			B1	R1 20030003			NO 2003-2310					-	0050	005		
MY	2003004976			D.	20030905			MX 2003-4976					20030604				
US	20040038951			A1	1 20040226			US 2003-433546					20030604				
US	US 6800643			В2	32 20041005			US 2003-433546  HK 2004-100918 US 2004-911201									
HK	1059564				A1		20080111			HK 2004-100918					20040211		
US	US 20050009795				A1		2005	0113		US 2	004-	9112	01		2	0040	804
US	70089	951			B2		2006	0307									

US 20060052352 JP 2007302684 PRIORITY APPLN. INFO.:	A1 A	20060309 20071122	JP GB EP JP WO US	2005-248462 2007-180977 2000-29562 2001-999366 2002-547487 2001-EP14122 2003-433546	A3 W A1	20051012 20070710 20001204 20011203 20011203 20011203 20030604
OTHER SOURCE(S):	MARPAT	137:37642	US	2004-911201	A3	20040804

AB An inhalation composition comprises, sep. or together, (A) a quinolinone compound

(I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, useful for simultaneous, sequential or sep. administration in the treatment of an inflammatory or obstructive airway disease. The molar ratio of (A) to (B) is from 100:1 to 1:300. A composition is an aerosol or a dry powder in a capsule. For example, an aerosol formulation was prepared by dispensing 10 parts of micronized I maleate, 10 parts of mometasone furcate, and 100 parts of lactose (bulking agent) into a vial, sealing the vial with a metering valve, injecting the premix of 2500 parts of ethanol, 30,500 parts of propellant HFA134a, 67,000 parts of propellant HFA227, and 0.5 parts of oleic acid (surfactant) into the vial through the valve, and subjecting the vial to ultrasonic energy to disperse the solid particles.

312753-06-3P TΤ

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and quinolinone compound and its formulation with corticosteroid

for treatment of airway disorders)

312753-06-3 CA

2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-CN vl)aminol-1-hvdroxvethvll-8-hvdroxv- (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT